 Kathryn Colborn
Concepts (436)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 11 | 2025 | 1069 | 2.650 |
Why?
| | Postoperative Complications | 30 | 2025 | 2654 | 2.240 |
Why?
| | Shock, Septic | 5 | 2025 | 219 | 1.350 |
Why?
| | Sepsis | 6 | 2023 | 617 | 1.250 |
Why?
| | Quality Improvement | 14 | 2023 | 1178 | 1.240 |
Why?
| | Urinary Tract Infections | 3 | 2022 | 188 | 1.210 |
Why?
| | Surgical Procedures, Operative | 5 | 2023 | 259 | 1.210 |
Why?
| | Surgical Wound Infection | 7 | 2025 | 307 | 1.190 |
Why?
| | Machine Learning | 8 | 2025 | 493 | 1.180 |
Why?
| | Pancreatic Neoplasms | 10 | 2024 | 938 | 1.160 |
Why?
| | Malaria | 4 | 2023 | 63 | 1.070 |
Why?
| | Retrospective Studies | 47 | 2025 | 15657 | 0.800 |
Why?
| | Postoperative Hemorrhage | 2 | 2023 | 86 | 0.780 |
Why?
| | Models, Statistical | 4 | 2020 | 669 | 0.770 |
Why?
| | Humans | 127 | 2025 | 137585 | 0.760 |
Why?
| | Malaria, Falciparum | 2 | 2018 | 27 | 0.750 |
Why?
| | Databases, Factual | 15 | 2025 | 1357 | 0.750 |
Why?
| | Pain | 2 | 2023 | 756 | 0.680 |
Why?
| | Plasmodium vivax | 2 | 2018 | 4 | 0.680 |
Why?
| | Malaria, Vivax | 2 | 2018 | 4 | 0.680 |
Why?
| | Adenocarcinoma | 5 | 2024 | 940 | 0.650 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 402 | 0.640 |
Why?
| | Artificial Intelligence | 1 | 2023 | 279 | 0.630 |
Why?
| | Palliative Care | 8 | 2025 | 758 | 0.630 |
Why?
| | Surgeons | 4 | 2025 | 297 | 0.610 |
Why?
| | Pneumonia | 3 | 2023 | 639 | 0.600 |
Why?
| | Risk Assessment | 17 | 2024 | 3457 | 0.590 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2253 | 0.590 |
Why?
| | Inpatients | 4 | 2023 | 500 | 0.580 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 30 | 0.560 |
Why?
| | Poisson Distribution | 1 | 2018 | 75 | 0.560 |
Why?
| | Thoracic Surgery | 3 | 2025 | 132 | 0.560 |
Why?
| | Health Plan Implementation | 1 | 2019 | 142 | 0.560 |
Why?
| | Neoadjuvant Therapy | 8 | 2024 | 404 | 0.560 |
Why?
| | Risk Factors | 25 | 2025 | 10388 | 0.520 |
Why?
| | Mosquito Control | 2 | 2023 | 28 | 0.520 |
Why?
| | Middle Aged | 40 | 2025 | 33479 | 0.520 |
Why?
| | Hospitalization | 6 | 2021 | 2199 | 0.500 |
Why?
| | Female | 57 | 2025 | 73304 | 0.480 |
Why?
| | Aged | 32 | 2025 | 23961 | 0.480 |
Why?
| | Quality of Life | 11 | 2025 | 2892 | 0.480 |
Why?
| | Mosquito Nets | 1 | 2015 | 2 | 0.480 |
Why?
| | Anopheles | 1 | 2015 | 16 | 0.470 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2023 | 289 | 0.470 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 301 | 0.450 |
Why?
| | Drug Prescriptions | 3 | 2021 | 245 | 0.440 |
Why?
| | Male | 50 | 2025 | 67762 | 0.440 |
Why?
| | Adult | 36 | 2025 | 37929 | 0.430 |
Why?
| | Thoracic Surgical Procedures | 2 | 2025 | 73 | 0.410 |
Why?
| | Mastectomy, Segmental | 2 | 2024 | 93 | 0.390 |
Why?
| | Ambulatory Surgical Procedures | 2 | 2023 | 66 | 0.380 |
Why?
| | Patient Discharge | 2 | 2020 | 897 | 0.380 |
Why?
| | Primary Health Care | 3 | 2025 | 1738 | 0.380 |
Why?
| | Hospital Mortality | 1 | 2016 | 911 | 0.370 |
Why?
| | Robotic Surgical Procedures | 2 | 2024 | 130 | 0.370 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 75 | 0.370 |
Why?
| | Preoperative Care | 3 | 2024 | 362 | 0.360 |
Why?
| | Algorithms | 4 | 2019 | 1704 | 0.360 |
Why?
| | Mastectomy | 4 | 2024 | 137 | 0.350 |
Why?
| | Child, Preschool | 15 | 2025 | 11074 | 0.340 |
Why?
| | Influenza, Human | 3 | 2021 | 622 | 0.330 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 515 | 0.330 |
Why?
| | Incidence | 8 | 2023 | 2804 | 0.330 |
Why?
| | Hospitals | 4 | 2025 | 691 | 0.320 |
Why?
| | Emergency Service, Hospital | 4 | 2025 | 2069 | 0.320 |
Why?
| | Emergency Treatment | 2 | 2021 | 118 | 0.320 |
Why?
| | Zebrafish | 2 | 2025 | 499 | 0.310 |
Why?
| | Heart Failure | 5 | 2025 | 2236 | 0.310 |
Why?
| | Colorado | 9 | 2025 | 4565 | 0.300 |
Why?
| | United States | 19 | 2025 | 14841 | 0.280 |
Why?
| | Cohort Studies | 11 | 2024 | 5742 | 0.280 |
Why?
| | Osteoarthritis, Knee | 2 | 2021 | 254 | 0.280 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7635 | 0.270 |
Why?
| | Research Design | 3 | 2022 | 1139 | 0.270 |
Why?
| | Pancreatectomy | 3 | 2024 | 253 | 0.270 |
Why?
| | Cardiac Surgical Procedures | 2 | 2023 | 530 | 0.270 |
Why?
| | Logistic Models | 5 | 2023 | 2074 | 0.270 |
Why?
| | Patient Satisfaction | 4 | 2024 | 660 | 0.270 |
Why?
| | Chagas Disease | 2 | 2018 | 44 | 0.260 |
Why?
| | Seasons | 3 | 2025 | 547 | 0.260 |
Why?
| | Prognosis | 10 | 2024 | 4030 | 0.260 |
Why?
| | Autism Spectrum Disorder | 2 | 2023 | 395 | 0.260 |
Why?
| | Mass Drug Administration | 3 | 2023 | 7 | 0.260 |
Why?
| | Rectal Neoplasms | 2 | 2019 | 149 | 0.260 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2021 | 363 | 0.240 |
Why?
| | Time-to-Treatment | 2 | 2025 | 205 | 0.240 |
Why?
| | Elective Surgical Procedures | 2 | 2024 | 179 | 0.240 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2024 | 389 | 0.240 |
Why?
| | Asthma | 1 | 2019 | 2295 | 0.230 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 72 | 0.230 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 22 | 0.230 |
Why?
| | Treatment Outcome | 13 | 2025 | 10811 | 0.220 |
Why?
| | Varicose Veins | 1 | 2024 | 17 | 0.220 |
Why?
| | Infant | 11 | 2025 | 9465 | 0.220 |
Why?
| | Heart Defects, Congenital | 2 | 2022 | 842 | 0.210 |
Why?
| | Hypothermia | 1 | 2023 | 36 | 0.210 |
Why?
| | Specialties, Surgical | 2 | 2021 | 75 | 0.210 |
Why?
| | Zebrafish Proteins | 2 | 2025 | 288 | 0.210 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 35 | 0.210 |
Why?
| | Metastasectomy | 1 | 2023 | 20 | 0.200 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 49 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 1000 | 0.200 |
Why?
| | Predictive Value of Tests | 4 | 2022 | 2031 | 0.200 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1509 | 0.200 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 42 | 0.200 |
Why?
| | Adolescent | 14 | 2025 | 21513 | 0.200 |
Why?
| | Insecticides | 1 | 2023 | 38 | 0.200 |
Why?
| | MEF2 Transcription Factors | 1 | 2022 | 61 | 0.200 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 65 | 0.200 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1313 | 0.200 |
Why?
| | Young Adult | 11 | 2020 | 13209 | 0.200 |
Why?
| | Risk Adjustment | 1 | 2023 | 78 | 0.200 |
Why?
| | Europe | 1 | 2023 | 414 | 0.200 |
Why?
| | Nervous System Diseases | 1 | 2025 | 266 | 0.190 |
Why?
| | Telemetry | 1 | 2022 | 40 | 0.190 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 45 | 0.190 |
Why?
| | Microcephaly | 1 | 2023 | 98 | 0.190 |
Why?
| | Carotid Stenosis | 1 | 2023 | 91 | 0.190 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 77 | 0.190 |
Why?
| | Polypharmacy | 1 | 2023 | 85 | 0.190 |
Why?
| | Medication Therapy Management | 1 | 2023 | 76 | 0.190 |
Why?
| | Syncope | 1 | 2022 | 52 | 0.190 |
Why?
| | Pneumonectomy | 1 | 2023 | 152 | 0.190 |
Why?
| | Galectins | 1 | 2022 | 24 | 0.190 |
Why?
| | Information Dissemination | 1 | 2024 | 218 | 0.190 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2019 | 43 | 0.190 |
Why?
| | Decision Support Systems, Clinical | 1 | 2025 | 226 | 0.180 |
Why?
| | Drug Hypersensitivity | 1 | 2023 | 90 | 0.180 |
Why?
| | Pain, Postoperative | 2 | 2021 | 265 | 0.180 |
Why?
| | Ivermectin | 1 | 2021 | 13 | 0.180 |
Why?
| | Mozambique | 2 | 2018 | 7 | 0.180 |
Why?
| | Delirium | 1 | 2023 | 92 | 0.180 |
Why?
| | Neuroendocrine Tumors | 1 | 2023 | 116 | 0.180 |
Why?
| | Ambulatory Care | 1 | 2025 | 546 | 0.180 |
Why?
| | Communication | 2 | 2025 | 879 | 0.170 |
Why?
| | Vascular Surgical Procedures | 1 | 2024 | 303 | 0.170 |
Why?
| | Program Evaluation | 3 | 2021 | 898 | 0.170 |
Why?
| | Oxycodone | 1 | 2021 | 42 | 0.170 |
Why?
| | Dysbiosis | 1 | 2022 | 181 | 0.170 |
Why?
| | New Guinea | 2 | 2018 | 4 | 0.170 |
Why?
| | Surgery Department, Hospital | 1 | 2020 | 20 | 0.170 |
Why?
| | Knee Joint | 2 | 2021 | 409 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2022 | 119 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1692 | 0.160 |
Why?
| | Arthroplasty | 1 | 2020 | 52 | 0.160 |
Why?
| | Terminal Care | 1 | 2023 | 232 | 0.160 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 46 | 0.160 |
Why?
| | Hypersensitivity | 1 | 2023 | 257 | 0.160 |
Why?
| | Faculty | 1 | 2021 | 147 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2022 | 238 | 0.160 |
Why?
| | Artemisinins | 1 | 2019 | 3 | 0.160 |
Why?
| | Antimalarials | 1 | 2019 | 31 | 0.160 |
Why?
| | Phenotype | 2 | 2025 | 3196 | 0.160 |
Why?
| | Intensive Care Units | 2 | 2022 | 827 | 0.160 |
Why?
| | Child | 12 | 2025 | 21935 | 0.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2019 | 142 | 0.150 |
Why?
| | Latent Tuberculosis | 1 | 2010 | 69 | 0.150 |
Why?
| | Prisons | 1 | 2010 | 81 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 255 | 0.150 |
Why?
| | Vaccination | 2 | 2025 | 1381 | 0.150 |
Why?
| | Waiting Lists | 2 | 2021 | 266 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 806 | 0.150 |
Why?
| | General Surgery | 1 | 2021 | 173 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 76 | 0.150 |
Why?
| | Laparoscopy | 1 | 2023 | 466 | 0.150 |
Why?
| | Healthcare Disparities | 3 | 2025 | 654 | 0.150 |
Why?
| | Rural Population | 2 | 2020 | 563 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 188 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 316 | 0.150 |
Why?
| | Aftercare | 1 | 2020 | 208 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2021 | 250 | 0.150 |
Why?
| | Defibrillators, Implantable | 1 | 2022 | 315 | 0.150 |
Why?
| | Triage | 1 | 2021 | 222 | 0.150 |
Why?
| | Datasets as Topic | 1 | 2019 | 121 | 0.150 |
Why?
| | Outpatients | 1 | 2022 | 396 | 0.150 |
Why?
| | Social Marketing | 1 | 2008 | 16 | 0.150 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1587 | 0.150 |
Why?
| | Hospitals, University | 1 | 2018 | 182 | 0.150 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 37 | 0.150 |
Why?
| | Cognition | 2 | 2023 | 1153 | 0.150 |
Why?
| | Ventricular Function | 1 | 2018 | 61 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 39 | 0.140 |
Why?
| | Reproductive Medicine | 1 | 2008 | 15 | 0.140 |
Why?
| | Community Participation | 1 | 2019 | 131 | 0.140 |
Why?
| | Quinolines | 1 | 2019 | 178 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2022 | 264 | 0.140 |
Why?
| | Computers, Handheld | 1 | 2018 | 25 | 0.140 |
Why?
| | Autistic Disorder | 1 | 2020 | 204 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 166 | 0.140 |
Why?
| | Burns | 1 | 2022 | 325 | 0.140 |
Why?
| | Climate | 1 | 2018 | 94 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 62 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 445 | 0.140 |
Why?
| | ROC Curve | 1 | 2019 | 554 | 0.140 |
Why?
| | Patient Admission | 1 | 2019 | 197 | 0.140 |
Why?
| | Geography | 1 | 2018 | 200 | 0.140 |
Why?
| | Condoms | 1 | 2008 | 103 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 98 | 0.140 |
Why?
| | Sentinel Surveillance | 1 | 2017 | 49 | 0.140 |
Why?
| | Immunoglobulin A | 1 | 2019 | 211 | 0.140 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2023 | 115 | 0.140 |
Why?
| | Safety-net Providers | 1 | 2019 | 119 | 0.140 |
Why?
| | Recovery of Function | 1 | 2021 | 653 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 115 | 0.130 |
Why?
| | Occupational Health | 1 | 2010 | 200 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 581 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 350 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 89 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2023 | 171 | 0.130 |
Why?
| | Qualitative Research | 1 | 2024 | 1386 | 0.130 |
Why?
| | Gastroenteritis | 1 | 2017 | 69 | 0.130 |
Why?
| | Cell Phone | 1 | 2017 | 76 | 0.130 |
Why?
| | Anxiety Disorders | 1 | 2010 | 377 | 0.130 |
Why?
| | Students, Medical | 1 | 2021 | 348 | 0.130 |
Why?
| | Influenza Vaccines | 1 | 2021 | 539 | 0.130 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 70 | 0.130 |
Why?
| | Parents | 1 | 2025 | 1347 | 0.130 |
Why?
| | Telemedicine | 1 | 2025 | 862 | 0.130 |
Why?
| | Membrane Glycoproteins | 1 | 2019 | 500 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2010 | 341 | 0.130 |
Why?
| | Fever | 1 | 2017 | 306 | 0.120 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2017 | 103 | 0.120 |
Why?
| | Patient Readmission | 2 | 2020 | 697 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 389 | 0.120 |
Why?
| | Alcoholism | 1 | 2023 | 807 | 0.120 |
Why?
| | Prospective Studies | 6 | 2025 | 7604 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2018 | 138 | 0.120 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5131 | 0.120 |
Why?
| | Morbidity | 3 | 2022 | 324 | 0.120 |
Why?
| | Models, Organizational | 1 | 2016 | 151 | 0.120 |
Why?
| | Melanoma | 1 | 2022 | 760 | 0.120 |
Why?
| | Humidity | 1 | 2015 | 50 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 388 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2022 | 855 | 0.120 |
Why?
| | Advance Care Planning | 1 | 2018 | 209 | 0.110 |
Why?
| | Mass Screening | 2 | 2020 | 1287 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2023 | 847 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 625 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 183 | 0.110 |
Why?
| | Diarrhea | 3 | 2023 | 184 | 0.110 |
Why?
| | Cannabidiol | 1 | 2016 | 119 | 0.110 |
Why?
| | Massage | 2 | 2010 | 43 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1120 | 0.110 |
Why?
| | Anticonvulsants | 1 | 2016 | 217 | 0.110 |
Why?
| | Emergency Medical Services | 1 | 2021 | 552 | 0.110 |
Why?
| | Time Factors | 5 | 2024 | 6828 | 0.110 |
Why?
| | Survival Rate | 3 | 2024 | 1972 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1783 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 464 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1946 | 0.110 |
Why?
| | Parasitemia | 1 | 2013 | 13 | 0.110 |
Why?
| | Chronic Pain | 1 | 2018 | 262 | 0.100 |
Why?
| | Research | 1 | 2016 | 451 | 0.100 |
Why?
| | Environmental Exposure | 1 | 2018 | 579 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1046 | 0.100 |
Why?
| | Indians, North American | 1 | 2009 | 643 | 0.100 |
Why?
| | Software | 1 | 2018 | 665 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2844 | 0.100 |
Why?
| | Medicaid | 1 | 2017 | 435 | 0.100 |
Why?
| | Epilepsy | 1 | 2016 | 333 | 0.100 |
Why?
| | Heart-Assist Devices | 1 | 2018 | 552 | 0.100 |
Why?
| | Axilla | 2 | 2023 | 47 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1477 | 0.090 |
Why?
| | Diagnostic Tests, Routine | 2 | 2024 | 110 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2023 | 310 | 0.090 |
Why?
| | Emergencies | 2 | 2025 | 164 | 0.090 |
Why?
| | Temperature | 1 | 2015 | 679 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 173 | 0.090 |
Why?
| | Washington | 2 | 2025 | 156 | 0.090 |
Why?
| | Patients | 2 | 2023 | 175 | 0.090 |
Why?
| | Pain Management | 2 | 2010 | 352 | 0.090 |
Why?
| | Prevalence | 3 | 2023 | 2734 | 0.090 |
Why?
| | Uganda | 2 | 2023 | 77 | 0.090 |
Why?
| | Age Factors | 4 | 2021 | 3295 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2757 | 0.090 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 352 | 0.090 |
Why?
| | Internship and Residency | 1 | 2021 | 1147 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2828 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2017 | 754 | 0.080 |
Why?
| | Laboratories | 2 | 2021 | 113 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 2129 | 0.080 |
Why?
| | Postoperative Period | 2 | 2021 | 342 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2526 | 0.080 |
Why?
| | Anti-HIV Agents | 1 | 2016 | 778 | 0.080 |
Why?
| | Guatemala | 2 | 2023 | 327 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 820 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 654 | 0.080 |
Why?
| | Lymph Nodes | 2 | 2023 | 491 | 0.080 |
Why?
| | Pandemics | 3 | 2023 | 1639 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2016 | 951 | 0.080 |
Why?
| | Anti-Bacterial Agents | 3 | 2025 | 1809 | 0.080 |
Why?
| | Biomedical Research | 2 | 2025 | 692 | 0.070 |
Why?
| | Surveys and Questionnaires | 4 | 2023 | 5778 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2023 | 1266 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2024 | 556 | 0.070 |
Why?
| | Echocardiography | 2 | 2022 | 642 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1622 | 0.070 |
Why?
| | Immunization Programs | 1 | 2009 | 213 | 0.070 |
Why?
| | Urban Population | 2 | 2020 | 479 | 0.060 |
Why?
| | Referral and Consultation | 2 | 2023 | 786 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 238 | 0.060 |
Why?
| | Length of Stay | 2 | 2023 | 1215 | 0.060 |
Why?
| | Insurance Coverage | 2 | 2017 | 230 | 0.060 |
Why?
| | Affect | 1 | 2008 | 292 | 0.060 |
Why?
| | Nebraska | 1 | 2025 | 18 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 36 | 0.060 |
Why?
| | Pilot Projects | 2 | 2023 | 1710 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2022 | 6079 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5472 | 0.050 |
Why?
| | Cytokines | 2 | 2023 | 2085 | 0.050 |
Why?
| | Acute Disease | 2 | 2017 | 1007 | 0.050 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1289 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 2389 | 0.050 |
Why?
| | Animals | 4 | 2025 | 36940 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2010 | 565 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 220 | 0.050 |
Why?
| | Motivational Interviewing | 1 | 2025 | 107 | 0.050 |
Why?
| | Herniorrhaphy | 1 | 2023 | 60 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 16 | 0.050 |
Why?
| | Community Health Workers | 1 | 2023 | 62 | 0.050 |
Why?
| | Health Facilities | 1 | 2023 | 84 | 0.050 |
Why?
| | Growth Disorders | 1 | 2023 | 86 | 0.050 |
Why?
| | Sternotomy | 1 | 2022 | 26 | 0.050 |
Why?
| | Death | 1 | 2023 | 119 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2022 | 21 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 274 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Papua New Guinea | 1 | 2012 | 9 | 0.050 |
Why?
| | Vomiting | 1 | 2023 | 130 | 0.050 |
Why?
| | Breast | 1 | 2023 | 151 | 0.050 |
Why?
| | Burn Units | 1 | 2022 | 48 | 0.050 |
Why?
| | Alleles | 1 | 2025 | 891 | 0.050 |
Why?
| | Cough | 1 | 2023 | 122 | 0.050 |
Why?
| | Stroke Volume | 1 | 2025 | 612 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 206 | 0.050 |
Why?
| | HIV Infections | 1 | 2016 | 2836 | 0.050 |
Why?
| | Neutrophil Infiltration | 1 | 2022 | 107 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2023 | 686 | 0.050 |
Why?
| | Inappropriate Prescribing | 1 | 2022 | 55 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1325 | 0.040 |
Why?
| | Demography | 1 | 2022 | 291 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2023 | 197 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 470 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 125 | 0.040 |
Why?
| | Gastrectomy | 1 | 2022 | 126 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 341 | 0.040 |
Why?
| | Preoperative Period | 1 | 2021 | 129 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Habits | 1 | 2020 | 49 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 225 | 0.040 |
Why?
| | Research Personnel | 1 | 2022 | 173 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 522 | 0.040 |
Why?
| | Lung | 2 | 2024 | 4060 | 0.040 |
Why?
| | Censuses | 1 | 2020 | 31 | 0.040 |
Why?
| | South Africa | 1 | 2021 | 222 | 0.040 |
Why?
| | Schools, Medical | 1 | 2021 | 147 | 0.040 |
Why?
| | Reoperation | 1 | 2023 | 573 | 0.040 |
Why?
| | Fear | 1 | 2023 | 338 | 0.040 |
Why?
| | Policy | 1 | 2021 | 150 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1236 | 0.040 |
Why?
| | Blood Proteins | 1 | 2022 | 252 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 499 | 0.040 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 45 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 242 | 0.040 |
Why?
| | Urination Disorders | 1 | 2019 | 13 | 0.040 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 10 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2019 | 45 | 0.040 |
Why?
| | Risk | 1 | 2022 | 912 | 0.040 |
Why?
| | Mentors | 1 | 2021 | 202 | 0.040 |
Why?
| | Leucovorin | 1 | 2019 | 81 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1389 | 0.040 |
Why?
| | Program Development | 1 | 2021 | 364 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2022 | 513 | 0.040 |
Why?
| | Kenya | 1 | 2019 | 118 | 0.040 |
Why?
| | Cardiovascular Nursing | 1 | 2018 | 3 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 405 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 343 | 0.040 |
Why?
| | Colombia | 1 | 2018 | 41 | 0.040 |
Why?
| | Survivors | 1 | 2022 | 493 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 558 | 0.040 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2019 | 148 | 0.040 |
Why?
| | Fluorouracil | 1 | 2019 | 208 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2010 | 275 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 2009 | 252 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2020 | 393 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2023 | 530 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1793 | 0.030 |
Why?
| | Rectum | 1 | 2019 | 185 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 137 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1276 | 0.030 |
Why?
| | Odds Ratio | 1 | 2010 | 1070 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 362 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2021 | 578 | 0.030 |
Why?
| | Viral Load | 1 | 2019 | 466 | 0.030 |
Why?
| | Proctitis | 1 | 2016 | 7 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 811 | 0.030 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1079 | 0.030 |
Why?
| | Mental Health | 1 | 2023 | 726 | 0.030 |
Why?
| | Latin America | 1 | 2016 | 93 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 787 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 327 | 0.030 |
Why?
| | Sexually Transmitted Diseases | 1 | 2008 | 161 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 268 | 0.030 |
Why?
| | Medically Uninsured | 1 | 2017 | 130 | 0.030 |
Why?
| | Prisoners | 1 | 2008 | 148 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 482 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1035 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 792 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2016 | 145 | 0.030 |
Why?
| | Self Care | 1 | 2018 | 380 | 0.030 |
Why?
| | Electrocardiography | 1 | 2018 | 629 | 0.030 |
Why?
| | Plant Extracts | 1 | 2016 | 202 | 0.030 |
Why?
| | Insurance, Health | 1 | 2017 | 283 | 0.030 |
Why?
| | Curriculum | 1 | 2021 | 992 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 588 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 849 | 0.030 |
Why?
| | Hemorrhage | 1 | 2019 | 722 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 816 | 0.030 |
Why?
| | Transcription Factors | 1 | 2022 | 1719 | 0.030 |
Why?
| | Mutation | 1 | 2025 | 3958 | 0.030 |
Why?
| | Neoplasms | 1 | 2008 | 2671 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3284 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3556 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2071 | 0.020 |
Why?
| | Health Promotion | 1 | 2008 | 741 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2837 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 4149 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2035 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 2992 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2008 | 282 | 0.020 |
Why?
| | Veterans | 1 | 2009 | 1476 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2009 | 986 | 0.010 |
Why?
|
|
Colborn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|